Algorithmic bias occurs when a model performs differently across subgroups (e.g., by sex, race, age, comorbidity) due to training data imbalance, label noise, or proxy variables. Fairness analyses quantify and mitigate these gaps. Regulators expect manufacturers to report performance by relevant subgroups and explain any gaps, rather than only overall accuracy. FDA's draft AI-enabled device guidance and the EU AI Act's data governance rules (Article 10) both address representativeness and bias. Mitigations include more diverse data collection, re-weighting, subgroup-specific thresholds, labeling of limitations and post-market monitoring of subgroup performance.

Why it matters

FDA's GMLP principles call for representative datasets and subgroup performance analysis. EU AI Act high-risk requirements explicitly address bias monitoring across the lifecycle.

Common pitfalls

•Failing to define fairness metrics relevant to the specific clinical context and patient population.
•Overlooking the potential for bias to be introduced or amplified at various stages of the AI/ML lifecycle, from data acquisition to deployment.
•Assuming that a globally accurate model is also fair across all demographic subgroups.

Sources

Good Machine Learning Practice · FDA/Health Canada/MHRA
IMDRF - Software as a Medical Device · IMDRF
MDCG Software Guidance · MDCG

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.